Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 12;9(2):23814683241264280.
doi: 10.1177/23814683241264280. eCollection 2024 Jul-Dec.

Young Adult and Parent Willingness to Pay for Meningococcal Serogroup B Vaccination

Affiliations

Young Adult and Parent Willingness to Pay for Meningococcal Serogroup B Vaccination

Liping Huang et al. MDM Policy Pract. .

Abstract

Introduction. Serogroup B (MenB) is the leading cause of invasive meningococcal disease among adolescents and young adults in the United States. The US Advisory Committee on Immunization Practices (ACIP) recommends MenB vaccination based on shared clinical decision making between patients and providers. However, suboptimal understanding of these recommendations could contribute to low vaccination awareness and coverage. Understanding young adult and parent expectations of their health care providers (HCPs) and the value they place on vaccine information could help inform a consistent approach to HCP MenB vaccination discussions and recommendations. Methods. Data collected via a discrete-choice experiment online survey were used to evaluate preferences and willingness to pay regarding MenB vaccination among US parents and young adults in 2019. Results. Of 2,388 respondents with valid data, 1,185 were parents of children aged 12 to 25 y, and 1,203 were young adults aged 18 to 25 y. Approximately 70% of parents and young adults indicated that they would react negatively if their HCP chose not to initiate a discussion with them about MenB vaccines. Neither parents nor young adults were willing to pay for additional time for MenB vaccine discussions with their HCP but were willing to pay an average of $416 and $282, respectively, for the vaccine. For parents and young adults, greater willingness to pay was associated with a provaccination attitude and the opinion that the HCP has a moral obligation to discuss the MenB vaccine with them. Conclusion. Both parents and young adults felt their HCP is responsible for initiating a discussion about MenB vaccination and disease risk and were willing to pay for the vaccine. These findings should help inform ACIP recommendations for meningococcal vaccination.

Highlights: ACIP recommends shared clinical decision making for MenB vaccination.Data were collected from young adults and parents of adolescents by online survey.We measured values and consultation preferences on MenB disease and vaccination.Young adults/parents strongly preferred doctor-initiated MenB vaccine discussion.Respondents were willing to pay for a MenB vaccine.

Keywords: contingent valuation method; meningococcal disease; serogroup B; shared clinical decision making; vaccines; willingness to pay.

PubMed Disclaimer

Conflict of interest statement

The work was presented at IDWeek 2020, SAHM 2020. The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: LH is a Pfizer employee and may hold stock options. AS is currently employed by Orbital Therapeutics; he was a Pfizer employee at the time of manuscript development and may hold stock options. AF reports Pfizer research support for consulting services. DW has no conflicts to report. RJ reports Pfizer research support to Duke University. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Pfizer Inc. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report.

Figures

Figure 1
Figure 1
Reaction to doctor choosing not to discuss MenB vaccine. *Average for the combined groups. Participants were asked on the survey, “Suppose your doctor did not discuss the vaccine with you, so you never knew it was an option. You found out later when a friend asked whether you got the vaccine. How would you feel about this situation?” Responses were then categorized by the interviewer as either “unconcerned,” “calm,” “understanding,” “concerned,” “disappointed,” “anxious or afraid,” “upset,” or “angry or disgusted.” MenB, meningococcal serogroup B.
Figure 2
Figure 2
Multinomial-logit log-odds estimates of “upset” or “concerned” versus “unconcerned.” Shown are the multinomial-logit estimates for a response of “upset” or “concerned” versus “unconcerned.” Values on the x-axis indicate the strength of the association between each demographic variable or characteristic and the likelihood that a respondent would indicate that they would be “upset” or “concerned” rather than “unconcerned” if their doctor neglected to discuss MenB vaccination. The responses of “disappointed,” “anxious or afraid,” “upset,” and “angry or disgusted” were grouped into a single “more concerned” category, and responses of “unconcerned,” “calm,” and “understanding” were grouped into a single “less concerned” omitted category. Error bars indicate 95% confidence intervals. CV, contingent valuation; MenB, meningococcal serogroup B; vax, vaccine; WTP, willingness to pay.
Figure 3
Figure 3
Factors associated with WTP for MenB vaccination. Statistically significant participant characteristics associated with WTP are shown. The change from the average WTP estimate for each statistically significant covariate is shown. The vertical line indicates the mean WTP. Error bars indicate 95% confidence intervals. MenB, meningococcal serogroup B; vax, vaccine; WTP, willingness to pay.

Similar articles

References

    1. Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59:S12–20. DOI: 10.1016/j.jadohealth.2016.03.041 - DOI - PubMed
    1. Peterson ME, Li Y, Bita A, et al.. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9:010409. - PMC - PubMed
    1. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–61. DOI: 10.1016/S1473-3099(10)70251-6 - DOI - PubMed
    1. Burman C, Serra L, Nuttens C, Presa J, Balmer P, York L. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother. 2019;15:459–69. DOI: 10.1080/21645515.2018.1528831 - DOI - PMC - PubMed
    1. World Health Organization. Meningococcal meningitis. 2018. Available from: http://www.who.int/en/news-room/fact-sheets/detail/meningococcal-meningitis. [Accessed 3 October, 2020].

LinkOut - more resources